Toripalimab Plus FLOT in Locally Advanced Gastric Cancer

Status Recruiting

Clinical Trial Summary

Neoadjuvant chemoimmunotherapy for locally advanced gastric and gastroesophageal junction (G/GEJ) cancer is currently under investigation. Most clinical studies have simply combined chemotherapy with anti-PD-1 therapy without considering the impact of chemotherapy drugs on activated immune cells. We designed this study to explore two different treatment regimens for neoadjuvant chemotherapy in patients with locally advanced G/GEJ cancer. One group received FLOT plus toripalimab on Day 1 of each cycle, every 2 weeks for 4 cycles, followed by surgery; the other group received FLOT plus toripalimab on Day 3 of each cycle, every 3 weeks for 3 cycles, followed by surgery. A total of 69 subjects were enrolled. Preliminary statistical analysis conducted one year after the last subject was enrolled revealed no statistically significant differences in pCR and MPR between the two regimens. The median DFS for both groups has not been reached, and there is no statistically significant difference in DFS between the two groups at present. Further subgroup analysis indicated that among subjects with PD-L1 CPS ≥1, the triweekly group achieved a rate of 42.1%, compared to 29.4% in the biweekly group, with no statistically significant difference between the two groups. However, the incidence of bone marrow suppression was lower in the triweekly group than in the biweekly group. Based on the preliminary findings, we plan to conduct an expanded study and transition to a multicenter clinical trial. This study aims to further validate the efficacy of the triweekly chemoimmunotherapy in patients with PD-L1 CPS ≥1 locally advanced G/GEJ cancer.

Clinical Trial Description

Eligible patients received FLOT combined with toripalimab on Day 3 every 3 weeks, for a total of 3 cycles, followed by surgical treatment. Postoperative adjuvant therapy was determined based on pathological results: if a pathological complete response (pCR) was achieved, patients received 2 additional cycles of the neoadjuvant regimen; if pCR was not achieved, patients were given 4 cycles of SOX combined with toripalimab postoperatively. ;

Study Design

Related Conditions & MeSH terms

Chemotherapy
Immune Checkpoint Inhibitor
Locally Advanced Gastric Carcinoma
Stomach Neoplasms

Clinical Trial Details

NCT number	NCT04891016
Study type	Interventional
Source	Henan Cancer Hospital
Contact	Quanli Gao, M.D
Phone	+8637165587483
Email	gaoquanli2015@126.com
Status	Recruiting
Phase	Phase 2
Start date	June 25, 2021
Completion date	December 31, 2028

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03652727` - FX vs. ECG Guidance for PICC Insertion	N/A
Not yet recruiting	`NCT05856656` - Music Therapy as a Tool for Anxiety Reduction in Localized Breast Cancer	N/A
Active, not recruiting	`NCT02959541` - PK/PD Investigation of Calciumfolinat in Blood, Tumor and Adjacent Mucosa in Patient With Colon Cancer	N/A
Completed	`NCT00757094` - Safety and Feasibility of Fasting While Receiving Chemotherapy	N/A
Recruiting	`NCT00797238` - DNA Repair Genes and Outcomes in Patients With Stage III NSCLC	N/A
Not yet recruiting	`NCT05927857` - Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer .	Phase 1/Phase 2
Recruiting	`NCT04453826` - Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma	Phase 3
Completed	`NCT04466332` - Comparison of Two ECG Guided PICC Insertion Techniques	N/A
Not yet recruiting	`NCT04055038` - Efficacy of Platinum-based Chemotherapy in Platinum-resistant Ovarian Cancer) (EPITOC)	Phase 2/Phase 3
Recruiting	`NCT03701607` - Effect of Chemotherapy on PD-L1 in NSCLC
Recruiting	`NCT04024241` - Medium Dose of Cytarabine and Mitoxantrone
Recruiting	`NCT06208436` - The Survival Outcome of Adjuvant Chemotherapy for Stage I Pancreatic Cancer
Recruiting	`NCT05306301` - Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients	Phase 2
Active, not recruiting	`NCT02304640` - Prevalence, Severity and Determinants of Cancer-related Fatigue (CRF) in Asian Breast Cancer Patients
Completed	`NCT02298972` - Symptom Support During Chemotherapy: A Mixed Method Study in Adult Patients With Cancer	N/A
Terminated	`NCT01249001` - Relative Bioavailability of an Extemporaneous Oral Suspension of Aprepitant in Adolescents	Phase 2
Recruiting	`NCT03089892` - A Perspective Study of Cancer-related Fatigue in Gynecologic Cancer Patients Under Chemotherapy	N/A
Recruiting	`NCT05125055` - Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC	Phase 2/Phase 3
Recruiting	`NCT04472403` - Platinum Plus Low-dose Long-term Continuous Intravenous Infused 5-Fluorouracil in Metastatic Nasopharyngeal Carcinoma
Terminated	`NCT02982694` - Study With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal Cancer	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.